Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2011 1
2012 1
2013 1
2014 2
2015 3
2016 3
2017 2
2018 2
2019 1
2020 4
2021 3
2022 6
2023 7
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, Nerviani A, Giorli G, Mahto A, Montecucco C, Lauwerys B, Ng N, Ho P, Bombardieri M, Romão VC, Verschueren P, Kelly S, Sainaghi PP, Gendi N, Dasgupta B, Cauli A, Reynolds P, Cañete JD, Moots R, Taylor PC, Edwards CJ, Isaacs J, Sasieni P, Choy E, Pitzalis C; R4RA collaborative group. Humby F, et al. Among authors: mahto a. Lancet. 2021 Jan 23;397(10271):305-317. doi: 10.1016/S0140-6736(20)32341-2. Lancet. 2021. PMID: 33485455 Free PMC article. Clinical Trial.
Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.
Rivellese F, Surace AEA, Goldmann K, Sciacca E, Çubuk C, Giorli G, John CR, Nerviani A, Fossati-Jimack L, Thorborn G, Ahmed M, Prediletto E, Church SE, Hudson BM, Warren SE, McKeigue PM, Humby F, Bombardieri M, Barnes MR, Lewis MJ, Pitzalis C; R4RA collaborative group. Rivellese F, et al. Nat Med. 2022 Jun;28(6):1256-1268. doi: 10.1038/s41591-022-01789-0. Epub 2022 May 19. Nat Med. 2022. PMID: 35589854 Free PMC article. Clinical Trial.
Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England.
Quick V, Abusalameh M, Ahmed S, Alkoky H, Bukhari M, Carter S, Coath FL, Davidson B, Doddamani P, Dubey S, Ducker G, Griffiths B, Gullick N, Heaney J, Holloway A, Htut EEP, Hughes M, Irvine H, Kinder A, Kurshid A, Lim J, Ludwig DR, Malik M, Mercer L, Mulhearn B, Nair JR, Patel R, Robson J, Saha P, Tansley S; TOC STOP 2022 Investigators; Mackie SL. Quick V, et al. Rheumatology (Oxford). 2023 Nov 11:kead604. doi: 10.1093/rheumatology/kead604. Online ahead of print. Rheumatology (Oxford). 2023. PMID: 37952183
Gout incidence and management during the COVID-19 pandemic in England, UK: a nationwide observational study using OpenSAFELY.
Russell MD, Massey J, Roddy E, MacKenna B, Bacon S, Goldacre B, Andrews CD, Hickman G, Mehrkar A, Mahto A, Rutherford AI, Patel S, Adas MA, Alveyn E, Nagra D, Bechman K, Ledingham JM, Hudson J, Norton S, Cope AP, Galloway JB. Russell MD, et al. Among authors: mahto a. Lancet Rheumatol. 2023 Oct;5(10):e622-e632. doi: 10.1016/S2665-9913(23)00206-0. Epub 2023 Aug 31. Lancet Rheumatol. 2023. PMID: 38251486 Free PMC article.
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials.
Rivellese F, Nerviani A, Giorli G, Warren L, Jaworska E, Bombardieri M, Lewis MJ, Humby F, Pratt AG, Filer A, Gendi N, Cauli A, Choy E, McInnes I, Durez P, Edwards CJ, Buch MH, Gremese E, Taylor PC, Ng N, Cañete JD, Raizada S, McKay ND, Jadon D, Sainaghi PP, Stratton R, Ehrenstein MR, Ho P, Pereira JP, Dasgupta B, Gorman C, Galloway J, Chinoy H, van der Heijde D, Sasieni P, Barton A, Pitzalis C; STRAP collaborative group. Rivellese F, et al. Lancet Rheumatol. 2023 Nov;5(11):e648-e659. doi: 10.1016/S2665-9913(23)00241-2. Lancet Rheumatol. 2023. PMID: 38251532 Free article. Clinical Trial.
A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients.
Nerviani A, Di Cicco M, Mahto A, Lliso-Ribera G, Rivellese F, Thorborn G, Hands R, Bellan M, Mauro D, Boutet MA, Giorli G, Lewis M, Kelly S, Bombardieri M, Humby F, Pitzalis C. Nerviani A, et al. Among authors: mahto a. Front Immunol. 2020 May 5;11:845. doi: 10.3389/fimmu.2020.00845. eCollection 2020. Front Immunol. 2020. PMID: 32431716 Free PMC article.
Incidence and management of inflammatory arthritis in England before and during the COVID-19 pandemic: a population-level cohort study using OpenSAFELY.
Russell MD, Galloway JB, Andrews CD, MacKenna B, Goldacre B, Mehrkar A, Curtis HJ, Butler-Cole B, O'Dwyer T, Qureshi S, Ledingham JM, Mahto A, Rutherford AI, Adas MA, Alveyn E, Norton S, Cope AP, Bechman K; OpenSAFELY Collaborative. Russell MD, et al. Among authors: mahto a. Lancet Rheumatol. 2022 Dec;4(12):e853-e863. doi: 10.1016/S2665-9913(22)00305-8. Epub 2022 Nov 3. Lancet Rheumatol. 2022. PMID: 36447940 Free PMC article.
36 results